A study published in JAMA Network, by the Case Western Reserve University examined about 15,11,637 eligible participants with ...

The Food and Drug Administration (FDA) has further expanded the U.S. indications of Novo Nordisk’s (NVO) popular weight loss ...

New research links two widely used diabetes drugs, semaglutide or tirzepatide, to a rare but potentially vision-threatening eye condition, raising questions about drug-specific risks and the need ...

To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...

The agency shared information from reports by users of compounded semaglutide and tirzepatide who have experienced health ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an increased risk of rare eye conditions.

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...